English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech
艾美疫苗公布全球发售结果 每股H股发售股份发售价为16.16港元
Oct 05, 2022 18:57 HKT
艾美疫苗公佈全球發售結果 每股H股發售股份發售價為16.16港元
Oct 05, 2022 18:56 HKT
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
Oct 05, 2022 18:55 HKT
多宁生物拟赴港上市:先发优势显著 业绩增长强劲
Oct 05, 2022 18:46 HKT
多寧生物擬赴港上市:先發優勢顯著 業績增長強勁
Oct 05, 2022 18:45 HKT
臻和科技递表港交所:NGS技术领衔业界 财务优势可圈可点
Oct 05, 2022 10:12 HKT
臻和科技遞表港交所:NGS技術領銜業界 財務優勢可圈可點
Oct 05, 2022 10:11 HKT
Bio Farma secures Multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)
Oct 04, 2022 07:00 HKT
Bio Farma to Export its Polio Vaccine After Securing Purchase Contracts from UNICEF for 2022 and 2023
Sep 30, 2022 18:00 HKT
Q&M Group awards 7 Dentists with Performance Shares, 12-year Service Agreements, and a Private Placement
Sep 30, 2022 15:00 HKT
아방스 클리니컬, 바이오테크 CRO 서비스 국제 보건상 수상
Sep 29, 2022 22:00 HKT
乐普生物PD-1单抗普佑恒(TM)获批新适应症,MRG003获CDE纳入突破性治疗药物名单
Sep 29, 2022 15:42 HKT
樂普生物PD-1單抗普佑恒(TM)獲批新適應症,MRG003獲CDE納入突破性治療藥物名單
Sep 29, 2022 15:41 HKT
Lepu Biopharma: Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC
Sep 29, 2022 15:40 HKT
臻和科技拟赴港上市:中国肿瘤分子诊断及检测的领导者 技术及财务共筑企业核心竞争力
Sep 29, 2022 14:35 HKT
臻和科技擬赴港上市:中國腫瘤分子診斷及檢測的領導者 技術及財務共築企業核心競爭力
Sep 29, 2022 14:34 HKT
Taiwan Stays at the Forefront of Medical Technology
Sep 29, 2022 13:00 HKT
Claudin18.2, a shining star in gastric cancer, Transcenta's TST001 stands at the global forefront
Sep 28, 2022 19:24 HKT
Avance Clinical Wins International Health Award for Biotech CRO Services
Sep 28, 2022 16:00 HKT
艾美疫苗宣布于港交所主板上市计划
Sep 23, 2022 17:19 HKT
Next >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: